Evolus Inc reports results for the quarter ended in January 1 - Earnings Summary

Evolus

07/11/2024 04:57

* Evolus Inc  EOLS.OQ  reported a quarterly adjusted loss
of 16
cents​​ per share for the quarter ended January 1, identical to
the same quarter last year.  The mean expectation of
six analysts for the quarter was for a loss of 10 cents per
share. Wall Street expected results to range from -14 cents
to -3 cents per share.
    * Revenue rose 22.1% to $61.09 million from a year ago;
analysts
expected $62.24 million. 
    * Evolus Inc's reported EPS for the quarter was a loss of 30
cents​.
    * The company reported a quarterly loss of $19.17 million.
    * Evolus Inc shares had risen by 1.8% this quarter and
gained 56.6% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 6% in
the last three months.​ 
    * In the last 30 days, two analysts negatively revised
earnings
estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"

Wall Street's median 12-month price target for Evolus Inc is
25.00 
This summary was machine generated from LSEG data November 7 at
04:56 a.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -0.10          -0.16          Missed
 Jun. 30 2024      -0.05          -0.04          Beat
 Mar. 31 2024      -0.10          -0.09          Beat
 Dec. 31 2023      -0.07          -0.12          Missed